Navigation Links
3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Date:7/10/2012

MENLO PARK, Calif., July 10, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today that George Kemble, PhD, Chief Scientific Officer, will present at the upcoming JMP Securities Healthcare Conference at the Peninsula Hotel in New York City.  Dr. Kemble will provide an overview of 3-V, including a discussion of both its lead program targeting the fatty acid synthase (FASN) pathway for the treatment of chronic hepatitis C virus (HCV) infection and the company's discovery platform.  Dr. Kemble's presentation will take place on Friday, July 13 at 12:00pm.

FASN is a cellular enzyme with increased expression following infection with HCV and in several cancers.  First-generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability.  3-V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and have the potential to become potent therapeutics for chronic HCV and other indications.

About 3-V Biosciences

3-V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance.  The 3-V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information Stephen R. Brady Chief Business Officer 650-561-8600


'/>"/>
SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Insmed To Present At JMP Securities 7th Annual Healthcare Conference
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Delcath To Present At JMP Securities Healthcare Conference On July 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Calif. , March 27, 2015 The ... life of myeloma patients while working toward prevention and ... (D-NY) for introducing a federal resolution (H. Res. ... March 2015 as "National Multiple Myeloma Awareness Month." ... with myeloma worldwide, and more than 110,000 new cases ...
(Date:3/27/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... focused on oncology with an emphasis on the ... the reporting of data from a single -center ... with the Delcath Hepatic Delivery System (Melphalan/HDS) and ... Society of Surgical Oncology (SSO) Annual Meeting 2015.  ...
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... /PRNewswire-Asia/ -- Synutra International, Inc. (Nasdaq: SYUT ... a producer, marketer and seller of nutritional products for ... will present at Citi,s Greater China Investor Conference to ... Macau.  Management is currently scheduled to meet with institutional ...
... one of the leading clinical trial procurement companies, is ... Clinical Trials Supplies: The New GCPs - Good Clinical ... Coast Conference in Philadelphia, Pennsylvania at the Hilton Philadelphia ... on Wednesday October 20th, and a link to register ...
Cached Medicine Technology:Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference 2Caligor Rx Presents Penn and USciences Bioethicist at the 2010 Clinical Trial Supply East Coast Conference 3
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for ... elbow injuries, according to new research released today at the ... Day. , “Our findings indicate that a 10 inch increase ... of a history of injury, a 10 mile per hour ... of a history of injury, and playing for more than ...
(Date:3/28/2015)... How best to treat and recover ... orthopaedic medicine. While diagnostic hip injections are commonly performed ... etiology, research presented today at the American Orthopaedic Society ... that pain relief from this diagnostic injection may not ... “Our study looked to assess if the amount of ...
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
Breaking Medicine News(10 mins):Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2
... ... ... WASHINGTON , March 17 The following is a statement by ... , , ...
... , TAMPA, Fla. , March 17 ... features to enhance its acclaimed study program for the ... exams. Effective immediately, 30 animated muscle tutorials, 25 interactive study ... nationwide. These features, which include narration for auditory learners, further ...
... understanding of the Skp2 gene and its relation to cellular ... can suppress tumor development in common types of cancer, researchers ... and Memorial Sloan-Kettering Cancer Center report in the journal ... cycle regulation, cell proliferation, cell growth and the formation of ...
... potentially deadly infections long has focused on looking for ways ... University of Utah and Utah State University shows that modulating ... save more lives. In a study published March ... U of U cardiologist Dean Y. Li, M.D., Ph.D., professor ...
... an indicator of more serious disease, study finds , ... bowel syndrome (IBS) aren,t at increased risk for polyps, ... disease and, in most cases, don,t require a colonoscopy, ... 10 percent to 20 percent of Americans, include recurrent ...
... WHEATON, Ill. , March 17 ... Organizational Planning, John Brady , DHA, has been ... with Disabilities Task Force. The Task Force is responsible ... changes, recommendations, and innovations may be needed to enhance ...
Cached Medicine News:Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 2Health News:More Money, Increased Participation and Higher Nutritional Standards for School Meals 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 2Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 4Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 5Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 6Health News:Disabling Skp2 gene helps shut down cancer growth 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 3Health News:Colonoscopy Not Needed for Most With Irritable Bowel Syndrome 2Health News:Marianjoy Vice President Named to Illinois' Disabilities Task Force 2
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L)....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
For the quantitative determination of Glucose in serum. Endpoint Reaction Product measured at 520 nm. Linearity: 500 mg/dl....
For the quantitative determination of Glucose in serum. Endpoint reaction (NAD -> NADH) measured at 340 nm. Linearity: 600 mg/dl. Liquid working reagent prepared with simple 1:9 dilution....
Medicine Products: